paragon28.com (FNA) - Long-Term Liabilities to Capital

Corporate emblem and logo of Paragon 28 Inc. (FNA)

Paragon 28, Inc. (FNA) is optimizing production by outsourcing the manufacture of standard titanium products to contractors while keeping engineering development in-house. As part of its ESG strategy, the brand is minimizing plastic waste and recycling tooling. Current price action on GURU.Markets, where the indicator stands at 0.80, complements the profile of this ankle fixation segment leader, which provides surgeons with comprehensive operative solutions to reduce surgical procedure times.

Long-Term Debt to Capital: Paragon 28 (FNA) for 07/04/2022 - 04/26/2025
Core merchandise of Paragon 28 Corp

An assessment of the debt load of Paragon 28, Inc. determines the financing stability of the orthopedic systems manufacturer's expansion. The current long-term debt-to-equity ratio stands at 0.80, reflecting the proportion of loans with maturities exceeding one year within the equity structure. A decrease in this ratio indicates deleveraging or growth in capitalization. For Paragon 28, Inc. (FNA), this balance is critical when updating its implant product line. Optimizing borrowings ensures financial flexibility while scaling sales of consumables.

Competing companies

Boston Scientific Corp - Long-Term Liabilities to Equity|Long-Term Debt to Capital EW|RMD - Long-Term Liabilities to Capital|Long-Term Debt to Capital PODD (Insulet Corporation)|ZBH - Long-Term Debt to Equity Ratio|CooperCompanies - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Invisalign ALGN|GMED: Long-Term Debt to Capital|TransMedics Group, Inc. (TMDX) - Long-Term Debt to Capital|Long-Term Debt to Equity Alphatec Holdings, Inc.|Long-Term Debt to Equity AORT|Long-Term Debt to Capital ENOV|Ratio of Long-Term Indebtedness to Capital Integra LifeSciences Corp|Motiva - Long-Term Debt to Equity Ratio|BBNX (iLet Bionic Pancreas) - Long-Term Liabilities to Equity|IRADIMED CORPORATION - Long-Term Debt to Capital|Long-Term Liabilities to Capital embecta.com|TNDM: Long-Term Debt to Capital|Long-Term Debt to Capital Ratio AXGN|Long-Term Debt to Equity Ratio SIBN|OFIX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Bioventus Inc. (BVS)|Long-Term Debt to Equity Ratio orthopediatrics.com KIDS|Long-Term Debt to Capital TMCI (Treace Medical Concepts, Inc.)|Blade Air Mobility (SRTA) - Long-Term Liabilities to Capital|Carlsmed Corp - Long-Term Debt to Capital|RXST (RxSight Ophthalmic) - Long-Term Debt to Capital Ratio|CLPT: Long-Term Debt to Capital|STXS - Ratio of Long-Term Indebtedness to Capital|STIM (Neuronetics) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Sight Sciences Inc. (SGHT)|Long-Term Debt to Capital OBIO|Long-Term Debt to Capital anikatherapeutics.com (ANIK)|Long-Term Debt to Equity InspireMD, Inc. NSPR|Jin Medical International Ltd. - Long-Term Debt to Equity|VANI: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient XTNT (Xtant Medical Holdings)|NMTC: Long-Term Debt to Capital|Long-Term Liabilities to Capital Modular Medical, Inc. (MODD)|Long-Term Debt to Equity Myomo, Inc.|COCH - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio VVOS (Vivos Therapeutics, Inc.)|Long-Term Debt to Capital enVVeno Medical Corporation (NVNO)|Long-Term Debt to Capital SINT (Sintx Technologies, Inc.)|Ratio of Long-Term Indebtedness to Capital Tenon Medical Inc (TNON)|LFWD - Long-Term Debt to Equity|Long-Term Liabilities to Equity AMIX|INVO Fertility (IVF) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Bone Biologics Corp.|AXNX (Axonics Modulation Technologies) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Biolase Inc. BIOL|Long-Term Debt to Equity Dynatronics Corporation (DYNT)|invobioscience.com - Long-Term Debt to Capital Ratio